Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Assets Average (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Assets Average for 15 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average rose 38.82% year-over-year to $1.5 billion, compared with a TTM value of $1.5 billion through Dec 2025, up 38.82%, and an annual FY2025 reading of $1.3 billion, up 32.53% over the prior year.
  • Assets Average was $1.5 billion for Q4 2025 at Arrowhead Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • Across five years, Assets Average topped out at $1.5 billion in Q4 2025 and bottomed at $628.0 million in Q1 2021.
  • Average Assets Average over 5 years is $917.1 million, with a median of $791.2 million recorded in 2022.
  • The sharpest move saw Assets Average dropped 12.1% in 2023, then skyrocketed 63.6% in 2025.
  • Year by year, Assets Average stood at $674.3 million in 2021, then increased by 17.41% to $791.7 million in 2022, then dropped by 12.1% to $695.9 million in 2023, then soared by 54.72% to $1.1 billion in 2024, then skyrocketed by 38.82% to $1.5 billion in 2025.
  • Business Quant data shows Assets Average for ARWR at $1.5 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.5 billion in Q2 2025.